Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.

Abstract: The present invention discloses a method for treating patients having the CDV associated symptoms or animals carrying or infected by the canine distemper virus (CDV) or having antibodies against the CDV using Product R, a peptide-nucleic acid preparation.

Abstract: This invention provides a vaccine which contains, per dose, an effective immunizing amount of an inactivated feline enteric coronavirus and a suitable carrier. The vaccine of this invention may also contain an adjuvant, an effective immunizing amount of a second inactivated virus and a an effective immunizing amount of an inactivated bacteria. Additionally provided by this invention is a method of immunizing a dog against disease caused by canine coronavirus involving administering to the dog a dose of the vaccine of this invention. The method of this invention may also involve administering one or more additional doses of vaccine to the dog, immunizing the dog against disease caused by a second virus and immunizing the dog against disease caused by a bacteria.

Abstract: A composition for treating diarrhea comprises carrots, rice, bananas and glucose in powdered form, the carrots and rice having been cooked and dried prior to being ground to a powder. The composition may also contain one or more of powdered pineapple, apples, soybeans and maltodextrin. An effective amount of the composition is administered to a patient, such as an infant, to treat and alleviate diarrhea.

Abstract: This invention relates to a method and composition for inhibiting or destroying viruses or retroviruses in a mammalian host. The method comprises contacting the viruses or retroviruses with a composition. The composition comprises an active ingredient capable of inhibiting or destroying viruses or retroviruses, for example, a surfactant, and an activating ingredient capable of inhibiting or destroying one or more enzymes associated with viruses or retroviruses, for example, a fluorinated compound capable of releasing fluoride anions, and an excipient.